These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23288235)

  • 21. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
    Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paliperidone-induced neuroleptic malignant syndrome.
    Nayak RB; Bhogale GS; Patil NM; Chate SS; Pandurangi AA; Shetageri VN
    J Neuropsychiatry Clin Neurosci; 2011; 23(1):E14-5. PubMed ID: 21304113
    [No Abstract]   [Full Text] [Related]  

  • 23. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paliperidone-associated motor tics.
    Hsieh MH; Chiu NY
    Gen Hosp Psychiatry; 2014; 36(3):360.e7-8. PubMed ID: 24556260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paliperidone overdose in a patient with schizophrenia.
    Chang JP; Huang CC; Su KP
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):418. PubMed ID: 19995588
    [No Abstract]   [Full Text] [Related]  

  • 26. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
    Teng PR; Lane HY
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E16-7. PubMed ID: 22231327
    [No Abstract]   [Full Text] [Related]  

  • 27. [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].
    Bellantuono C; Santone G
    Riv Psichiatr; 2012; 47(1):5-20. PubMed ID: 22358213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Manic symptoms during a switch from risperidone to paliperidone: a case report.
    Yang FW; Liang CS
    J Neuropsychiatry Clin Neurosci; 2011; 23(3):E29. PubMed ID: 21948917
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of priapism associated with paliperidone.
    Wearne D
    Aust N Z J Psychiatry; 2014 Oct; 48(10):962. PubMed ID: 24740252
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral-paliperidone-induced tardive dyskinesia: a case report.
    Wei HT; Lai YW; Chen MH; Chen YS
    Gen Hosp Psychiatry; 2012; 34(5):578.e5-6. PubMed ID: 22154659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paliperidone Palmitate-Induced Retrograde Ejaculation.
    Madan R; Langenfeld RJ; Ramaswamy S
    Clin Schizophr Relat Psychoses; 2018; 12(2):86-88. PubMed ID: 26780600
    [No Abstract]   [Full Text] [Related]  

  • 33. The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.
    Peritogiannis V; Tsouli S
    J Clin Psychiatry; 2011 Jul; 72(7):1016; author reply 1016-7. PubMed ID: 21824463
    [No Abstract]   [Full Text] [Related]  

  • 34. New drugs: paliperidone, dasatinib, and decitabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013
    [No Abstract]   [Full Text] [Related]  

  • 35. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.
    Han C; Lee SJ; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):650-1. PubMed ID: 21163319
    [No Abstract]   [Full Text] [Related]  

  • 36. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.
    Harrington CA; English C
    Int Clin Psychopharmacol; 2010 Nov; 25(6):334-41. PubMed ID: 20706126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.
    Vázquez-Bourgon J; Rodríguez-Rodríguez P; Gómez-Ruíz E; Artal J; Crespo-Facorro B
    Ann Clin Psychiatry; 2014 Nov; 26(4):301-2. PubMed ID: 25401718
    [No Abstract]   [Full Text] [Related]  

  • 38. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
    Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinsonism and rabbit syndrome after discontinuation of low-dose ziprasidone and concomitant initiation of sertraline.
    Gray JA
    J Clin Psychopharmacol; 2012 Feb; 32(1):142-3. PubMed ID: 22217953
    [No Abstract]   [Full Text] [Related]  

  • 40. Possible neuroleptic malignant syndrome during paliperidone administration: a case report.
    Mantas C; Kalabokis G; Goulia P; Tourlakopoulos A; Hyphantis T; Mavreas V
    J Clin Psychopharmacol; 2010 Feb; 30(1):89-91. PubMed ID: 20075663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.